Obesity isn't just about weight gain—it's a complex condition that can lead to serious health issues like insulin resistance and adipose tissue fibrosis. But here's where it gets controversial: what if a single protein, produced by specific cells in our fat tissue, plays a starring role in this harmful process? Recent groundbreaking research using single-cell RNA sequencing has uncovered a surprising culprit: Fibulin-7 (FBLN7), a glycoprotein that might be driving fibrosis in adipose tissue (AT).
Fibrosis occurs when there's an overproduction of the extracellular matrix (ECM), the scaffolding that supports our cells. In the context of obesity, this excessive ECM buildup contributes to AT dysfunction and metabolic complications. Scientists have long suspected that adipogenic stem and precursor cells (ASPCs) are key players in this process, but the exact mechanisms remained unclear—until now. By employing single-cell RNA-seq, researchers identified a distinct subset of ASPCs intimately linked to ECM production and fibrosis.
And this is the part most people miss: within this subset, FBLN7 emerged as a major player. In obese mice, FBLN7 expression was significantly elevated, mirroring findings in humans where higher FBLN7 levels in visceral fat correlated with metabolic issues. But it doesn't stop there—functional studies revealed that knocking out FBLN7 specifically in ASPCs led to reduced AT fibrosis and inflammation, alongside improved metabolic health. Conversely, overexpressing FBLN7 exacerbated these fibrogenic responses.
So, how does FBLN7 do this? Mechanistically, it interacts with thrombospondin-1 (TSP1) through its EGF-like calcium-binding domain, stabilizing TSP1 and promoting the activation of latent TGF-β. This, in turn, activates TGFBR1/Smad signaling pathways, driving fibrosis. To take it a step further, researchers developed an anti-FBLN7 neutralizing antibody that effectively reduced diet-induced AT fibrosis, positioning FBLN7 as a promising therapeutic target.
But here's the controversial question: If targeting FBLN7 could potentially reverse fibrosis and improve metabolic health, why isn't this already a mainstream treatment? Could there be unintended consequences of inhibiting this protein? These findings, published in Protein & Cell (Yu, H., et al., 2025), open the door to exciting possibilities but also raise important questions. What do you think? Is FBLN7 the key to tackling obesity-related fibrosis, or are we missing something critical? Share your thoughts in the comments below!
